Monitoring Tumor Response with Radiolabeled Nucleoside Analogs in a Hepatoma-Bearing Mouse Model Early After Doxisome (R) Treatment

作者：Wu Chun Yi; Chou Lin Shan; Chan Pei Chia; Ho Chung Hsien; Lin Ming Hsien; Shen Chih Chieh; Liu Ren Shyan^*; Lin Wuu Jyh; Wang Hsin Ell

来源：Molecular Imaging and Biology, 2013, 15(3): 326-335.

DOI：10.1007/s11307-012-0604-9

• Hepatoma
• Doxisome((R))
• PET
• F-18-FLT
• Therapeutic efficacy

This study aims to demonstrate that 3%26apos;-deoxy-3%26apos;-F-18-fluorothymidine (F-18-FLT) positron emission tomography (PET) is a promising modality for noninvasively monitoring the therapeutic efficacy of Doxisome(A (R)) in a subcutaneous hepatoma mouse model. %26lt;br%26gt;Male BALB/c nu/nu mice were inoculated with HepG2 hepatoma xenograft in the right flank. Doxisome(A (R)) (5 mg/kg, three times a week for 2 weeks) was intravenously administrated for treatment. F-18-FLT-microPET, biodistribution studies, and immunohistochemistry of Ki-67 were performed. %26lt;br%26gt;A significant difference (p %26lt; 0.05) in tumor volume was observed on day 5 between treated and control groups. The tumor-to-muscle ratio derived from F-18-FLT-PET and I-123-ICdR-microSPECT images of Doxisome(A (R))-treated mice dropped from 12.55 A +/- 0.76 to 3.81 A +/- 0.31 and from 2.48 A +/- 0.42 to 1.59 A +/- 0.08 after a three-dose treatment, respectively, while that of the control group remained steady. The retarded proliferation rate of treated xenograft was confirmed by Ki-67 immunohistochemistry staining. %26lt;br%26gt;This study clearly demonstrated that Doxisome(A (R)) is an effective anti-cancer drug against the growth of HepG2 hepatoma and that F-18-FLT-PET could provide early information of tumor response during treatment.

• 出版日期2013-6